Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma by Andersen, Ulrik O. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
Andersen, Ulrik O.; Terzic, Dijana; Albrechtsen, Nicolai Jacob Wewer; Mark, Peter Dall;
Plomgaard, Peter; Rehfeld, Jens F.; Gustafssons, Finn; Goetze, Jens P.
Published in:
Endocrine Connections
DOI:
10.1530/EC-19-0563
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Andersen, U. O., Terzic, D., Albrechtsen, N. J. W., Mark, P. D., Plomgaard, P., Rehfeld, J. F., ... Goetze, J. P.
(2020). Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. Endocrine
Connections, 9(5), 438-444. https://doi.org/10.1530/EC-19-0563
Download date: 10. sep.. 2020
9:5 438–444U Ø Andersen et al. Sacubitril/valsartan increases 
gastrin and CCK
RESEARCH
Sacubitril/valsartan increases postprandial 
gastrin and cholecystokinin in plasma
Ulrik Ø Andersen1,2, Dijana Terzic1,2, Nicolai Jacob Wewer Albrechtsen1,2,3, Peter Dall Mark1,2, Peter Plomgaard1,4, 
Jens F Rehfeld1, Finn Gustafsson5 and Jens P Goetze1,2
1Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
2Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3Novo Nordisk Foundation Centre for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
Correspondence should be addressed to J P Goetze: JPG@dadlnet.dk
J P Goetze is a member of the editorial board of Endocrine Connections. He was not involved in the editorial or peer review process of this paper, on 
which he is listed as an author
Abstract
Aims: Neprilysin degrades natriuretic peptides in circulation and is also suggested to 
degrade the gut hormones gastrin and cholecystokinin. Neprilysin inhibition has become 
a therapeutic strategy and thus a regimen in need of further testing in terms of other 
hormonal axes besides natriuretic peptides. The aim of this study was to examine 
whether acute inhibition of neprilysin affects meal-induced responses in gastrin and 
cholecystokinin concentrations in healthy individuals.
Methods and results: Nine healthy young men were included in an open-labelled, 
randomized cross-over clinical trial. The participants received a standardized meal (25 g fat, 
26 g protein, 42 g carbohydrate) on two separate days with or without a one-time dosage 
of sacubitril ((194 mg)/valsartan (206 mg)). Blood pressure, heart rate and blood samples 
were measured and collected during the experiment. Statistical differences between groups 
were assessed using area under the curve together with an ANOVA with a Bonferroni post 
hoc test. Sacubitril/valsartan increased the postprandial plasma concentrations of both 
gastrin and cholecystokinin (80% (AUC0-270 min, P = 0.004) and 60% (AUC0-270 min, P = 0.003), 
respectively) compared with the control meal. No significant hemodynamic effects were 
noted (blood pressure, AUC0-270 min, P = 0.86, heart rate, AUC0-270 min, P = 0.96).
Conclusion: Our study demonstrates that sacubitril/valsartan increases the postprandial 
plasma concentrations of gastrin and cholecystokinin in healthy individuals. The results 
thus suggest that neprilysin-mediated degradation of gastrin and cholecystokinin 
is physiologically relevant and may have a role in heart failure patients treated with 
sacubitril/valsartan.
Introduction
Chronic heart failure is treated by inhibition of the 
sympathetic and the renin-angiotensin-aldosterone 
system (RAAS). More recently, sacubitril/valsartan has 
been introduced as treatment for patients with chronic 
heart failure. The drug is composed of valsartan, an 
angiotensin-II receptor 1 blocker, and sacubitril, which 
inhibits the peptide-degrading enzyme neprilysin 
(neutral endopeptidase 24.11) (1). Neprilysin degrades a 
plethora of peptide hormones, including atrial (ANP) and 
B-type (BNP) natriuretic peptides (2). Increased plasma 
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concentrations of natriuretic peptides counteract the 
detrimental circulatory effects of heart failure, as they 
improve cardiac pre- and afterload by enhancing renal 
excretion of sodium and water, and also via vasodilatory 
effects. Importantly, it has also been shown that sacubitril/
valsartan reduces the mortality for patients with chronic 
heart failure (3).
Several other hormones, for instance glucagon-like 
peptide-1 (GLP-1) and substance P, are known substrates 
of neprilysin (1, 4). So far, only indirect experiments 
have suggested that neprilysin degrades gastrin and 
cholecystokinin (CCK) (5, 6, 7, 8, 9, 10). These hormones 
are secreted in parallel with GLP-1 from the endocrine gut 
after food intake. Gastrin regulates gastric acid secretion 
and growth of the fundic mucosa (11), whereas CCK 
regulates gallbladder contraction, satiety, and pancreatic 
exocrine and endocrine secretion (11, 12). Patients with 
chronic heart failure are now treated with sacubitril/
valsartan on a long-term basis, and it is therefore important 
to fully acknowledge the effects on all gut hormones. We 
thus examined the possible effects of acute neprilysin 
inhibition on the postprandial plasma concentrations of 
gastrin and CCK in healthy individuals.
Methods
The study was designed as an open-labelled, randomized 
trial and performed at the Department of Clinical 
Biochemistry (Rigshospitalet, University of Copenhagen). 
The Ethical Committee of The Capital Region of 
Denmark approved the protocol (H-18000360) and the 
study conformed to the Declaration of Helsinki. Before 
entering the trial, all subjects were informed in both oral 
and written form of the study protocol and the potential 
risks. At a consultation, height and weight were measured, 
and blood was collected as a general health check. Based 
on the results of the consultation, the subjects were 
either included or excluded. Eligible subjects were young, 
lean, and healthy males, all Caucasian. The inclusion 
and exclusion criteria are shown in Table 1. The study 
protocol and patient characteristic has been reported 
previously (13).
Study design
The subjects were enrolled for two study days separated 
by a 2-week washout period. The entire study was carried 
out over a period of 3 months. The subjects were initially 
randomized to receive either sacubitril/valsartan or no 
treatment on the first day of examination. Regardless of 
randomization, subjects fasted overnight (10 h) and the 
tests were performed the following morning. The subjects 
were placed in a supine position and a peripheral venous 
catheter was inserted into the cubital vein. On the day of 
treatment, two tablets of sacubitril/valsartan, 97 mg/103 
mg (C09DX04) (total dose of 194 mg sacubitril/206 mg 
valsartan) were administrated orally (t = 0 min). On both 
days of examination, a standardized meal (a Big Mac 
burger containing 42 g carbohydrate, 25 g fat, and 26 g 
protein) (Big Mac, McDonalds; https ://ww w.mcd onald 
s.com /dk/d a-dk/ produ ct/bi g-mac .html ) was ingested 
(t = 30 min). The meal was consumed within 5 min on 
both trial days. The dose for sacubitril/valsartan was 
chosen from the suggested doses for patients with heart 
failure; the time between the consumption of the drug 
and the beginning of meal intake was chosen on the 
basis of the given information for peak concentration of 
sacubitrilat in plasma (1–2 h).
During each trial day, a total of 12 blood samples per 
subject were collected in 6 mL ethylene diamine tetra-
acetate, and 4 mL lithium-heparin tubes at −30, 0, 15, 30, 
45, 60, 75, 90, 120, 150, 210, and 270 min; see Fig. 1. The 
tubes were immediately centrifuged for 10 min at 2000 g 
at 4°C, and the plasma was transferred to tubes (Cryopure, 
ref. 72.379; Sarstedt, Nümbrecht, Germany) and false 
Table 1 Criteria of inclusion and exclusion.
Inclusion criteria Exclusion criteria
Healthy Drugs consumption
Male Weight loss cure
Aged 18–30 years Donation of blood the past 2 weeks
BMI between 20 and 25 kg/m2 Daily medicine
Non-smoker Normal blood sample results at the first consultation
No use of daily medicine Smoker
Weekly alcohol intake above 21 units
Pre-blood samples showing sign of disease
Table 1 list the in- and exclusion criteria of this study.
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bottom tubes (ref. 60.614.010; Sarstedt) and stored at 
−80°C. During the study, the subjects were allowed to 
drink a maximum of 500 mL of water.
Biochemical analyses
The plasma from the inclusion examination was 
analysed for standard biochemical parameters (COBAS 
8000, Roche). During the trial, blood pressure and heart 
rate (HR) were measured using an Edan M3A Vital sign 
monitor. Plasma glucose was measured on a Cobas 8000, 
c702 module. Radioimmunoassays (RIAs) developed in 
the department were used to quantitate gastrin and CCK 
concentrations in plasma. The analytical and clinical 
validity of the RIAs has previously been reported (14, 
15, 16). In brief, gastrin and CCK were measured using 
antiserum 2604 and antiserum 92128, respectively, which 
bind all bioactive forms of the two hormones and with no 
cross-reactivity between the two.
Statistical analyses
Data are presented as mean values with s.e.m. if not 
otherwise indicated. In the statistical analyses, we 
compared the mean value of the outcomes between the 
two trial days. Area under the curve (AUC) was calculated 
using the trapezoidal method and used to conduct a 
paired T-test. In addition, a mixed model ANOVA was 
used to compare gastrin CCK and gastrin concentrations 
with the control group followed by the Bonferroni post hoc 
test. The mixed-model ANOVA was chosen due to missing 
data at a few time-points. A two-way ANOVA followed by 
a post hoc Bonferroni was used to determine any potential 
differences of mean arterial pressure (MAP), HR, and 
glucose concentrations. For the statistical analysis, the 
program Prism 8 for Windows (Graphpad) was used. The 
level of significance was set at P value <0.05.
Results
Ten healthy male subjects were screened for inclusion in 
the study. One dropped out after the initial consultation 
due to problems with adhering to the timeline of the 
study. The remaining subjects completed both trial days. 
Prior to the study, all subjects underwent a medical 
examination with all results within reference ranges. For 
baseline characteristics, see Table 2.
Hemodynamic response
Baseline mean arterial pressure (MAP) was 91 ± 2 mmHg 
in the control group and 88 ± 2 mmHg in the sacubitril/
valsartan group (two-way ANOVA, P > 0.99). In response to 
the ingestion of the meal, MAP decreased in both groups, 
but increased steadily 2 h after ingestion: There were no 
significant difference between the groups (tAUC0-270 min: 
−762 ± −1125 vs −652 ± -1089 min × mmHg, P = 0.86). In 
Figure 1
The subjects were fasting from 21:30 h the day before. A periphery venous catheter (PVC) was inserted, and baseline blood samples were collected 
before ingestion of sacubitril/valsartan (a total of 194 mg sacubitril/206 mg valsartan). The standardized meal (42 g carbohydrate, 25 g fat, 26 g protein) 
was consumed 30 min after ingestion of the drug. Red arrows indicate when blood samples, blood pressure (BP), and heart rate (HR) were collected and 
measured.
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parallel, heart rate (HR) decreased in both groups during 
the 30 min before ingestion of the meal. No response 
to ingestion of sacubitril/valsartan was observed, but in 
response to food intake, HR increased in both groups 
with a peak of 67 ± 3 bpm in the sacubitril/valsartan 
group vs 62 ± 3 bpm in the control group. No significant 
difference (tAUC0-270 min: 52 ± 63 sacubitril/valsartan 
group vs 46 ± 57 control group min × bpm, P = 0.98) was 
noted between trial the days.
Glucose concentration
There was no significant difference in glucose plasma 
concentration in response to ingestion of sacubitril/
valsartan and a meal between the two groups (peak 
6.7 ± 0.3 vs 6.7 ± 0.2 mmol/L, P > 0.99: tAUC0-270 min: 76 ± 93 
vs 63 ± 81, P = 0.67).
Gastrin and CCK response
The gastrin concentration in plasma rapidly increased 
after consumption of the standardized meal. Combined 
with intake of sacubitril/valsartan, the increase was 
markedly enhanced; AUC was 80% greater compared 
with the control group (tAUC0-270 min: 1263 ± 56 vs 710 ± 77 
min × pmol/L, P = 0.004, Fig. 2A). Ninety minutes after 
meal intake, the concentrations were similar in the two 
groups and they continued to be so throughout the 
remaining study period.
The baseline CCK concentrations in plasma did 
not differ between the trial days (mixed model ANOVA, 
P > 0.99). The plasma concentration increased after 
ingestion of a meal with and without sacubitril/valsartan. 
The AUC was 60% higher when subjects received 
sacubitril/valsartan (tAUC0-270 min: 487 ± 207 vs. 308 ± 115 
min × pmol/L, P = 0.003); see Fig. 2B.
Discussion
The present study shows that acute inhibition of 
neprilysin with sacubitril/valsartan increases the 
postprandial plasma concentrations of gastrin and 
cholecystokinin (CCK) in healthy young men. Previous 
studies have suggested a proteolytic effect of neprilysin 
on gastrin and CCK using indirect methods (7, 8, 9, 17, 
18, 19). Specifically, the effect of neprilysin was suggested 
through chromatographic comparison of endogenous 
peptide fragments with incubation of synthetic peptides 
and enzyme in vitro. A major difference between our study 
and the earlier in vitro studies was the former use of CCK 
and gastrin synthetic peptides together with neprilysin of 
non-human origin, which complicates the interpretation 
in relation to human physiology. One human study 
(9) did infuse human gastrin (gastrin-17) into healthy 
humans and evaluated the circulating fragments over 
time using gel chromatography. The study concluded on a 
possible degrading effect of neprilysin. However, no direct 
link was established to specific neprilysin degradation. 
The results of our human study show that targeted 
neprilysin inhibition immediately alters the gastrin and 
CCK concentrations after a meal in healthy young men.
The present report is mainly an exploratory study. 
The drug is indicated for patients with chronic heart 
failure and reduced ejection fraction, thus receiving daily 
drug doses for years. The long-term effect of neprilysin 
inhibition on gastrin and CCK concentrations is still 
unknown, but it seems reasonable to hypothesize that the 
plasma concentrations will also increase in patients with 
heart failure and during chronic therapy. Gastrin regulates 
proliferation and growth of the gastric mucosa and studies 
have indicated that long-term hypergastrinemia in 
humans induces hyperplasia and dysplasia of the gastric 
mucosa (20, 21, 22). It is unknown if the peaks of gastrin 
seen in this study is sufficient to induce hyperplasia in 
human. Whether hypergastrinemia will follow long-term 
treatment with sacubitril/valsartan needs to be examined, 
and if so, whether this increase is associated with an 
increase in gastric disorders such as dyspeptic pain and 
duodenal ulcers.
Table 2 Subject data.
Reference Mean s.e.m.
Height (cm) – 185 2
Weight (kg) – 81 2
Age (years) – 24 1
BMI (kg/m2) – 24 1
Hb (mmol/L) 8.3–9.5 9.3 0.2
K (mmol/L) 3.5–4.4 4.1 0.1
Creatinine (µmol/L) 60–105 85.8 4.6
Sodium (mmol/L) 137–145 140.2 0.7
Albumin (g/L) 36–48 42.2 0.8
CRP (mg/L) <5 1.1 0.1
ALAT (U/L) 10–70 26.1 5.0
HbA1C (IFCC) (mmol/
mol)
31–44 30.8 0.9
Glucose (mmol/L)a 4.2–6.3 5.3 0.1
Total cholesterol 
(mmol/L)
<5 4.2 0.3
HDL (mmol/L) >1 1.3 0.1
LDL (mmol/L) <3 2.8 0.4
Triglycerides (mmol/L) <2 1.1 0.4
Table 2 list the anthropometrics and biochemical results at consultation 
before entering the study.
aGlucose reference interval is in a fasting state, but the blood samples 
were collected at a pre-interview in a not-fasting state.
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A seminal study on sacubitril/valsartan treatment 
in heart failure patients has shown improved glycemic 
control in patients with both chronic heart failure and 
diabetes (23). While it remains unresolved exactly how 
sacubitril/valsartan improves the glycemic control, several 
mechanisms have been suggested including increased 
plasma concentrations of the incretin hormone GLP-1 
(23). We have recently reported that sacubitril/valsartan 
increases total but not intact GLP-1 concentrations in 
healthy humans (13). Other hormonal contributors 
behind the decrease in HbA1c values observed in patients 
could be CCK and gastrin, as both are also incretin 
hormones. The endocrine pancreas expresses gastrin/
CCK2 receptors, and several studies have shown that 
these hormones have an insulinotropic effect (24, 25, 
26, 27). Another possibility could be that CCK inhibits 
gastric motility (28), which will delay gastric emptying. 
This could also contribute to reducing the postprandial 
hyperglycemia seen in type 2 diabetes. Whether the 
earlier observed decrease in HbA1c is mediated mainly 
by one hormone system or, rather, several operating 
in concert, needs to be examined further. Finally, it 
should be recapitulated that a treatment which improves 
hemodynamic function in heart failure also will have an 
(positive) impact in physical activity of the patients and 
thereby contribute to decrease in HbA1c.
Gastrin and CCK both circulate in multiple molecular 
forms (29). The differences between the molecular 
forms are mainly defined by the N-terminal part of their 
structuresa, whereas the active/receptor binding part 
of the hormones resides in the C-terminal sequence. In 
this study, we only used immunoassays specific for the 
receptor binding part of the hormones, and as such, we 
thus report on the concentrations of the bioactive parts 
of gastrin and CCK. Several proteases are involved in the 
elimination of gastrin and CCK peptides, and mainly the 
N-terminus of CCK peptides is subject to cleavage and 
degradation in vivo by aminopeptidases. In contrast, the 
predominant gastrin forms (gastrin-34 and gastrin-17) are 
protected against aminopeptidases by pyroglutamination. 
In perspective, examining the different molecular forms 
of gastrin and CCK in relation to NEP inhibition could 
prove worthwhile to pursue.
This exploratory study has several limitations. 
Treatment with sacubitril/valsartan is indicated for 
patients with chronic heart failure, and this study was 
conducted on young healthy male subjects. A second 
limitation is the chosen dosage. The recommended dosage 
of sacubitril/valsartan is 49 mg/51 mg through weeks 
of upscaling until an endpoint of 97 mg/103 mg, twice 
daily. In this study, the subjects received two tablets of 97 
mg/103 mg, a total of 194 mg sacubitril/206 mg valsartan, 
once. This is two- to four-fold the recommended dosage, 
and it would, therefore, be relevant to examine if subjects 
receiving the clinical dosage have the same response 
as this study shows. Finally, this is an acute study of 
sacubitril/valsartan treatment, and whether the effect of 
long-term use of sacubitril/valsartan augments gastrin 
and CCK concentrations in circulation in patients with 
chronic heart failure is not clear.
In conclusion, this exploratory study shows that acute 
neprilysin inhibition with sacubitril/valsartan increases 
the meal-related concentrations of gastrin and CCK in 
plasma. Further studies including patients with chronic 
Figure 2
The subjects were randomized to not receive (blue circles) or to receive a 
single dose of two tablets of sacubitril/valsartan (a total of 194 mg 
sacubitril/206 mg valsartan) (green squares) and afterward a standardized 
meal. The red arrow represents the time sacubitril/valsartan was given 
and the grey arrow indicates administration of the standardized meal. 
Panel A and B shows the effect on gastrin and CCK concentrations, 
respectively.
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heart failure receiving sacubitril/valsartan are now 
needed to clarify the potential effects and their possible 
association to stomach-related disease.
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